{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-017164","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2026-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.604322+00:00","generated_at":"2026-05-16T09:21:14.598561+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"IO Biotech to explore strategic alternatives including merger, sale, or liquidation","bullets":["Company to evaluate merger, business combination, sale of assets, or liquidation and dissolution.","Further reduction-in-force and cost-cutting measures are also under consideration.","No timetable for the process; no assurance any transaction will occur.","IO Biotech (Nasdaq: IOBT) is a clinical-stage cancer vaccine developer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-017164","json":"https://secwatch.observer/filing/0001193125-26-017164.json","markdown":"https://secwatch.observer/filing/0001193125-26-017164.md","text":"https://secwatch.observer/filing/0001193125-26-017164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312526017164/0001193125-26-017164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312526017164/d26457d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:21:14.598561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}